Fully informing patients of the limitations of Saxenda use will ensure that the right patients are using Saxenda for the right reasons and that they will be appropriately monitored. Attachment 1. Product Information The PI approved for Saxenda at the time this AusPAR was published is at Attachment 1. For the most recent PI, please refer to the TGA website at <>. Attachment 2. Extract from the Clinical Evaluation Report
Fully informing patients of the limitations of Saxenda use will ensure that the right patients are using Saxenda for the right reasons and that they will be appropriately monitored. Attachment 1. Product Information The PI approved for Saxenda at the time this AusPAR was published is at Attachment 1. For the most recent PI, please refer to the TGA website at <>. Attachment 2. Extract from the Clinical Evaluation Report
auspar-liraglutide-160323.docx